CollPlant Biotechnologies (CLGN) Net Income towards Common Stockholders (2017 - 2025)

CollPlant Biotechnologies has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$3.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 20.73% year-over-year to -$3.2 million; the trailing twelve-month figure through Mar 2026 stood at -$3.5 million (down 41.31% YoY), and the FY2025 full-year result was -$11.1 million, up 32.76% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$3.2 million, up from -$3.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $193.9 million in Q3 2021, with the low at -$5.1 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged $9.3 million across 5 years, with a median of -$3.0 million in 2021.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders soared 698.75% — and 2022, when it slumped 102.3%.
• CollPlant Biotechnologies' Net Income towards Common Stockholders stood at -$3.8 million in 2021, then decreased by 22.92% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then climbed by 21.59% to -$4.0 million in 2024, then grew by 20.73% to -$3.2 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$3.2 million (Q4 2025), -$3.5 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.